Egpa: Eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome) as a special presentation of chronic rhinosinusitis with nasal polyps (CRSwNP)

Research output: Contribution to journalReview articleContributedpeer-review

Contributors

  • Jan Hagemann - , Center for Rhinology and Allergology Wiesbaden (Author)
  • Martin Laudien - , University Hospital Schleswig-Holstein Campus Kiel (Author)
  • Sven Becker - , University Hospital Tübingen (Author)
  • Mandy Cuevas - , Department of Otorhinolaryngology, Head and Neck Surgery (Author)
  • Felix Klimek - , Center for Rhinology and Allergology Wiesbaden (Author)
  • Roya Kianfar - , Center for Rhinology and Allergology Wiesbaden (Author)
  • Ingrid Casper - , Center for Rhinology and Allergology Wiesbaden (Author)
  • Ludger Klimek - , Center for Rhinology and Allergology Wiesbaden (Author)

Abstract

INTRODUCTION: Eosinophilic granulomatosis with polyangiitis (EGPA) was formerly known as Churg-Strauss syndrome. The condition is characterized by disseminated necrotizing vasculitis with extravascular granulomas associated with hypereosinophilia. The vasculitides affect small vessels and are associated with antineutrophil cytoplasmic antibodies (ANCAs) detectable in the blood. Distinguishing between type 2-mediated chronic airway inflammation such as chronic rhinosinusitis with nasal polyps (CRSwNP) without vasculitis can be clinically challenging and should be considered.

MATERIALS AND METHODS: Immunological background, diagnosis, and therapy of EGPA were identified through literature searches in Medline, PubMed, as well as national and international studies (ClinicalTrials.gov) and the Cochrane Library. Human studies published up to and including 10/2023 on the topic were considered.

RESULTS: In cases of deteriorating general health with previously known eosinophilic inflammation of the upper and lower airways, EGPA and its interdisciplinary investigation should be considered. Various types of eosinophilic inflammation and syndromes must be considered differentially.

CONCLUSION: Characterization of mucosal airway inflammation through biomarker determination is meaningful and occasionally makes the difference for targeted therapy.

Details

Original languageEnglish
Pages (from-to)18-25
Number of pages8
JournalAllergologie select
Volume8
Issue number3
Publication statusPublished - 2024
Peer-reviewedYes

External IDs

PubMedCentral PMC10975735
Scopus 85188432419
ORCID /0009-0007-1117-2210/work/200631843

Keywords

Sustainable Development Goals